A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial

Autor: Colin G. Miller, Henning Grønbæk, Irene Virgolini, Andreas Kjaer, Pierre Terve, Shadfar Bahri, Peter Iversen, Hanna Svirydenka, Thomas Rohban, Sandy McEwan

Publikováno v: EJNMMI Research, Vol 11, Iss 1, Pp 1-11 (2021)

Abstract Background 68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist exhibiting higher tumour-to-background ratios and sensitivity compared to 68Ga-DOTATOC. This randomised, 2 × 3 factorial, phase II study aimed to confirm the

Externí odkaz: https://doaj.org/article/4c8b1bb0808c480fadaf97e8afe9d6a7

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Autor: Ulrich Knigge, Shadfar Bahri, Johannes Czernin, Peter Iversen, Andreas Kjaer, Esben Andreas Carlsen, Christine Powell, Johanna Maffey-Steffan, Henning Grønbæk, Irene Virgolini, Sandy McEwan, Colin G. Miller, Mathias Loft, Thomas Rohban

Publikováno v: Virgolini, I, Bahri, S, Kjaer, A, Gronbaek, H, Iversen, P, Carlsen, E A, Loft, M, Knigge, U, Maffey-Steffan, J, Powell, C, Miller, C G, Rohban, T, McEwan, S & Czernin, J 2022, ' A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68 Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors ', Journal of Nuclear Medicine, vol. 63, no. 3, pp. 376-383 . https://doi.org/10.2967/jnumed.121.261936
Virgolini, I, Bahri, S, Kjaer, A, Gronbaek, H, Iversen, P, Carlsen, E A, Loft, M, Knigge, U, Maffey-Steffan, J, Powell, C, Miller, C G, Rohban, T, McEwan, S & Czernin, J 2022, ' A randomised, factorial phase II study to determine the optimal dosing regimen for 68 Ga-satoreotide trizoxetan as an imaging agent in patients with gastroenteropancreatic neuroendocrine tumours ', Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 63, no. 3 . https://doi.org/10.2967/jnumed.121.261936

68Ga-satoreotide trizoxetan is a novel somatostatin receptor antagonist associated with high sensitivity and reproducibility in neuroendocrine tumour (NET) detection and localisation. However, the optimal peptide mass and radioactivity ranges for 68G

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46b7d8b3fed34544124a81cf18e8ced
https://pure.au.dk/portal/da/publications/a-randomized-factorial-phase-ii-study-to-determine-the-optimal-dosing-regimen-for-68gasatoreotide-trizoxetan-as-an-imaging-agent-in-patients-with-gastroenteropancreatic-neuroendocrine-tumors(efd7ada3-d130-4069-aa7e-652d008e0f37).html

A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for

Autor: Irene, Virgolini, Shadfar, Bahri, Andreas, Kjaer, Henning, Grønbæk, Peter, Iversen, Esben A, Carlsen, Mathias, Loft, Ulrich, Knigge, Johanna, Maffey-Steffan, Christine, Powell, Colin G, Miller, Thomas, Rohban, Sandy, McEwan, Johannes, Czernin

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 63(3)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ef7c40f7b6aecbc439e188eb97da20de
https://pubmed.ncbi.nlm.nih.gov/34215673

Penicillin-resistant Streptococcus pneumoniae in Lebanon: the first nationwide study

Autor: Thomas Rohban, Rita Baroud-Nassif, Marwan Uwaydah, Jacques E. Mokhbat, Dolla Karam-Sarkis

Publikováno v: International Journal of Antimicrobial Agents. 27:242-246

A total of 123 clinical isolates of Streptococcus pneumoniae were collected from all over Lebanon and tested for their susceptibility to penicillin: 30.1% were susceptible (minimum inhibitory concentration (MIC)or = 0.06 microg/mL), 56.1% were interm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::942bf82b71e6064eb1947bea1e63c720
https://doi.org/10.1016/j.ijantimicag.2005.10.019